Table 2.
Pipeline containing (pre) clinical studies on monoclonal antibodies targeting infectious diseases
| Disease | Preclinical* | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|---|
| Diarrheal disease | |||||
| non-typhoid Salmonella spp. | 4 | no studies | no studies | no studies | no studies |
| Shigella spp | 1 | no studies | no studies | no studies | no studies |
| Yersinia enterocolitica | no studies | no studies | no studies | no studies | no studies |
| Campylobacter jejuni | 1 | no studies | no studies | no studies | no studies |
| Vibrio cholerae | 2 | no studies | no studies | no studies | no studies |
| Enterotoxigenic E. coli | 4 | no studies | no studies | no studies | no studies |
| Entamoeba histolytica | no studies | no studies | no studies | no studies | no studies |
| Cryptosporidium spp. | 1 | no studies | no studies | no studies | no studies |
| Giardia lamblia | no studies | no studies | no studies | no studies | no studies |
| Cyclospora | no studies | no studies | no studies | no studies | no studies |
| Viral syndromes | |||||
| Dengue | 15 | AV-1 | no studies | no studies | no studies |
| DenguShield | |||||
| Zika | 17 | Tyzivumab | no studies | no studies | no studies |
| DMAb-ZK190 | |||||
| Chikungunya | 23 | mRNA-1944 | no studies | no studies | no studies |
| SAR440894 | |||||
| Japanese encephalitis | 2 | no studies | ImmunoRel | no studies | no studies |
| West Nile Virus | 4 | MGAWN1 | MGAWN1 | no studies | no studies |
| Tick-borne encephalitis | 3 | no studies | no studies | no studies | no studies |
| Rift Valley fever | 4 | no studies | no studies | no studies | no studies |
| Yellow fever | 5 | TY014 | no studies | no studies | no studies |
| Ebola Virus Disease | 47 | mAb114 (Ansuvimab) | Ansuvimab | Ansuvimab | Ansuvimab |
| REGN3470-3471–3479 (REGN-EB3) | REGN-EB3 | REGN-EB3 | REGN-EB3 | ||
| Ebola (03-AT-2017) (GamEMab) | Gamezumab (01-AT-2020) | Gamezumab | |||
| Zmapp | Zmapp | ||||
| Lassa | 3 | no studies | no studies | no studies | no studies |
| Marburg | 9 | no studies | no studies | no studies | no studies |
| Crimean Congo HF | 3 | no studies | no studies | no studies | no studies |
| Hanta virus | 6 | no studies | no studies | no studies | no studies |
| Hepatitis A | no studies | no studies | no studies | no studies | no studies |
| Hepatitis B | 10 | Lenvervimab | Envafolimab | no studies | no studies |
| HH-006 | FG-3019 | ||||
| HH-003 | Cetrelimab | ||||
| HepB mAb19 | HLX-10 | ||||
| IMC-I109V | HH-003 | ||||
| HepeX-B | |||||
| Hepatitis C | 14 | Bavituximab | anti-CD3 | no studies | Tremelimumab |
| MD11X06-02 | MBL-HCV1 | ||||
| XTL6865 | CT-011 | ||||
| CT-011 | Anti-IL2R | ||||
| Hepatitis E | 1 | no studies | no studies | no studies | no studies |
| Mpox | 4 | no studies | no studies | no studies | no studies |
| Malaria | |||||
| Plasmodium spp. | 14 | CIS43LS | CIS43LS | no studies | no studies |
| L9LS | L9LS | ||||
| TB31F | |||||
| MAM01 | |||||
| Meplazumab | |||||
| Rabies | |||||
| Rabies virus | 8 | CL184 | CL184 | SII RMAb | SII RMAb |
| SII RMAb | SII RMAb | SYN023 | |||
| SYN023 | SYN023 | GR1801 | |||
| Rabies mAb CBB1 | Docaravimab/ miromaviab |
Docaravimab/ miromavimab |
|||
| Ormutivimab | Ormutivimab | ||||
| Trypanosomiasis | |||||
| Trypanosomia cruzi | 5 | no studies | no studies | no studies | no studies |
| Schistosomiasis | |||||
| Schistosoma spp. | 1 | no studies | no studies | no studies | no studies |
| Tuberculosis | |||||
| Mycobacterium tuberculosa | 3 | no studies | Pascolizumab | no studies | no studies |
| Other | |||||
| Leptospirosis | 1 | no studies | no studies | no studies | no studies |
| Typhoid fever | 1 | no studies | no studies | no studies | no studies |
| Melioidosis | 1 | no studies | no studies | no studies | no studies |
| Rickettsioses | no studies | no studies | no studies | no studies | no studies |
| Strongyloidiasis | no studies | no studies | no studies | no studies | no studies |
| Leishmaniasis | 6 | SCH708980 | SCH708980 | no studies | no studies |
*Preclinical studies: number indicates articles published before 21 of October 2023 (Pubmed) containing in vivo data on pipeline monoclonal antibodies. Clinical phases 1,2,3,4 also contain unpublished studies found on the registry clinicaltrial.gov (up until 21 of October 2023). Crimean Congo HF Crimean Congo hemorrhagic fever